Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics

EBS POWR Grades

• Value is the dimension where EBS ranks best; there it ranks ahead of 99.05% of US stocks.
• The strongest trend for EBS is in Sentiment, which has been heading down over the past 178 days.
• EBS's current lowest rank is in the Sentiment metric (where it is better than 2.92% of US stocks).

EBS Stock Summary

• The price/operating cash flow metric for EMERGENT BIOSOLUTIONS INC is higher than only 12.32% of stocks in our set with a positive cash flow.
• EBS's price/sales ratio is 0.39; that's higher than the P/S ratio of only 12.76% of US stocks.
• As for revenue growth, note that EBS's revenue has grown -8.42% over the past 12 months; that beats the revenue growth of only 14.87% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to EMERGENT BIOSOLUTIONS INC, a group of peers worth examining would be COHU, ONTO, CSGS, AIM, and SQL.
• Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.

EBS Valuation Summary

• EBS's price/sales ratio is 0.4; this is 91.67% lower than that of the median Healthcare stock.
• EBS's price/sales ratio has moved down 2.5 over the prior 195 months.

Below are key valuation metrics over time for EBS.

EBS Growth Metrics

The year over year cash and equivalents growth rate now stands at -20.44%.
• Its 5 year revenue growth rate is now at 126.65%.
• Its 2 year revenue growth rate is now at 58.62%.

Over the past 33 months, EBS's revenue has gone up $407,400,000.

The table below shows EBS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	1,513.4	202.1	53.5
2022-06-30	1,602.4	292.8	96.5
2022-03-31	1,757.2	278.7	157.5
2021-12-31	1,792.7	321.1	230.9
2021-09-30	1,652.5	237.2	227
2021-06-30	1,708.7	325.7	299.2

EBS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• EBS has a Quality Grade of C, ranking ahead of 50.38% of graded US stocks.
• EBS's asset turnover comes in at 0.604 -- ranking 57th of 681 Pharmaceutical Products stocks.
• ARWR, IBIO, and MCRB are the stocks whose asset turnover ratios are most correlated with EBS.

The table below shows EBS's key quality metrics over time.